Insights into the impact of sodium‐glucose cotransporter 2 inhibition on urinary tract malignancy: A two‐sample Mendelian randomization

The authors have no conflicts of interest to declare. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15490. The data used in this study are publicly available and all GWAS data used can be found in the IEU Open GWAS project (https://gwas.mrcieu.ac.uk/), GWAS Catalogue (https://www.ebi.ac.uk/gwas/), GTEx (https://www.gtexportal.org/) and eQTLGEN Consortium (https://www.eqtlgen.org/phase1.html). Figure S1. Scatter plots of the SGLT2 inhibition in the discovery (A) prostate cancer, (B) bladder cancer, (C) renal cell carcinoma (male), and (D) renal cell carcinoma (female) genome-wide association studies. Figure S2. Leave one out analyses of the SGLT2 inhibition in the discovery (A) prostate cancer, (B) bladder cancer, (C) renal cell carcinoma (male), and (D) renal cell carcinoma (female) genome-wide association studies. Figure S3. Forest plots of the SGLT2 inhibition in the discovery (A) prostate cancer, (B) bladder cancer, (C) renal cell carcinoma (male), and (D) renal cell carcinoma (female) genome-wide association studies. Figure S4. Funnel plots of the SGLT2 inhibition in the discovery (A) prostate cancer, (B) bladder cancer, (C) renal cell carcinoma (male), and (D) renal cell carcinoma (female) genome-wide association studies. Figure S5. Leave one out analyses of the SGLT2 inhibition in the replication (A) prostate cancer, (B) bladder cancer, and (C) renal cell carcinoma genome-wide association studies. Figure S6. Scatter plots of the SGLT2 inhibition in the replication (A) prostate cancer, (B) bladder cancer, and (C) renal cell carcinoma genome-wide association studies. Figure S7. Forest plots of the SGLT2 inhibition in the replication (A) prostate cancer, (B) bladder cancer, and (C) renal cell carcinoma genome-wide association studies. Figure S8. Funnel plots of the SGLT2 inhibition in the replication (A) prostate cancer, (B) bladder cancer, and (C) renal cell carcinoma genome-wide association studies. Figure S9. Combined results from the discovery and replication of (A) prostate cancer, (B) bladder cancer, and (C) renal cell carcinoma genome-wide association studies. a, discovery dataset; b, replication dataset. Table S1. Baseline characteristics of included SNPs. Table S2. Associated traits of included SNPs from the Phenoscanner website. Table S3. Sources of genome-wide association study data are included in the discovery and replication dataset. Table S4. Results of SGLT2 inhibition on urological cancers in the discovery and replication genome-wide association studies. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.